Latest Conference Articles

April 13th 2021, 12:53pm

AACR Annual Meeting

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

April 12th 2021, 11:15pm

AACR Annual Meeting

Treatment with D-0316 demonstrated encouraging clinical activity in select patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior therapy.

April 12th 2021, 9:00pm

AACR Annual Meeting

Administering the investigational TKI poziotinib at a twice-daily dose compared with once-daily dosing showed a reduction in both grade 3 or higher treatment emergent adverse effects and dose interruptions, as well as improved efficacy in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

April 12th 2021, 7:55pm

AACR Annual Meeting

The combination of the PARP inhibitor talazoparib and carboplatin demonstrated synergistic activity in 7 cell lines of triple-negative breast cancer, with greater DNA damage and cell death observed in PARP inhibitor–resistant cell lines and at lower concentrations of talazoparib when combined with carboplatin.

April 12th 2021, 7:10pm

AACR Annual Meeting

Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.

April 12th 2021, 6:51pm

AACR Annual Meeting

Richard Gorlick, MD, discussed results from a study examining the use of integrative surfaceome profiling to identify immunotherapeutic targets in patients with osteosarcomas.

April 12th 2021, 5:34pm

AACR Annual Meeting

Adavosertib plus irinotecan showed early activity in a cohort of pediatric patients with neuroblastoma, thus meeting the protocol-defined efficacy end point of the 1/2 ADVL1312 trial.

April 12th 2021, 4:50pm

AACR Annual Meeting

The activity and safety of investigational combinations will be subject to study in patients with advanced clear cell renal cell carcinoma (ccRCC) as part of a phase 1b/2 umbrella platform trial.

April 12th 2021, 12:44pm

AACR Annual Meeting

The combination of the selective MCL-1 inhibitor AMG 176 plus gilteritinib was found to synergistically target preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.

April 12th 2021, 12:16am

AACR Annual Meeting

Neratinib in combination with fulvestrant was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, although the clinical benefit rate did not meet the predefined efficacy criteria.

April 11th 2021, 10:34pm

AACR Annual Meeting

The combination of tislelizumab and sitravatinib demonstrated early antitumor activity and a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.

April 11th 2021, 7:27pm

AACR Annual Meeting

The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.

April 11th 2021, 4:33pm

AACR Annual Meeting

Patients with non‒small cell lung cancer whose circulating tumor MET Exon 14 is undetectable following treatment with savolitinb are more likely to have positive outcomes.

April 11th 2021, 4:15pm

AACR Annual Meeting

Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion–positive gastrointestinal cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion–driven cancers.

April 11th 2021, 4:00pm

AACR Annual Meeting

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

April 11th 2021, 3:27pm

AACR Annual Meeting

Selpercatinib demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects, manageable early onset toxicity, and low rates of treatment discontinuation, in patients with RET-altered advanced solid tumors.

April 11th 2021, 3:14pm

AACR Annual Meeting

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

April 11th 2021, 2:39pm

AACR Annual Meeting

The tumor-infiltrating lymphocyte therapy lifileucel was found to elicit durable responses in patients with advanced melanoma who were previously treated with an immune checkpoint inhibitor.

April 10th 2021, 11:14pm

AACR Annual Meeting

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma.

April 10th 2021, 9:01pm

AACR Annual Meeting

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature.